Literature DB >> 30697024

Low cost reconstructive options after musculoskeletal tumour resection in developing countries. Affordable, effective and durable alternatives.

Arif Ali1, Obada Hasan1, Ahmed Habib1, Masood Umer1.   

Abstract

Over the last two, three decades, the overall survival rates for non-metastatic malignant tumours of the bone have dramatically improved. This has become possible due to the recent advances and multidisciplinary approach towards these diseases, specifically the advent of multi-agent chemotherapy and radiotherapy. Limb salvage has now become the norm in the treatment of musculoskeletal tumours without compromising on the overall survival and recurrence of the disease. In the era of metal, prosthetic reconstruction has become the standard procedure specifically in the large tumours which involve the joints as this method of reconstruction helps in joint mobility and early weight-bearing. Considering the costs and resource constraints, multiple cost-effective, stable, durable reconstruction options have evolved over the last decade and these have also shown favourable func tional outcomes without compromising on the amount of resection and risk of local recurrence. The current literature review was planned to discuss various cost-effective, durable reconstructive options and their advantages and disadvantages. These include Van ness rotationplasty, allograft, autograft, devitalised tumour bone and Masqueletor induced membrane technique . .

Entities:  

Keywords:  Musculoskeletal, Tumour, Orthopaedic, O nc ology, R econ str uc ti on, Developing country.

Mesh:

Year:  2019        PMID: 30697024

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  1 in total

1.  Modified Borggreve-Van Nes-Winkelmann rotationplasty for surgery in developing countries.

Authors:  Laura Sommerauer; Aung Phyo; Eric Pion; Isabel Zucal; Eric Klingelhoefer; Si Thu; Than Win; Sopyay Khin; Thura Kyaw; Hein Htet Zaw; Maung Mg Htwe; Nicola Fabbri; Silke Haerteis; Thiha Aung
Journal:  BMC Surg       Date:  2022-09-07       Impact factor: 2.030

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.